A patch-clamp technique in a whole-cell configuration was used to examine functional activity of recently developed 2-fluoro-3-(substituted phenyl)deschloroepibatidine analogs on two major subtypes of neuronal nAChRs, α4β2 and α3β4, that predominate in the central and peripheral nervous system, respectively. These epibatidine analogs have been shown previously to possess high binding affinity to α4β2 but not to α7 nAChRs and to inhibit nicotine-induced analgesia in behavioral pain tests. The 2-fluoro-3-(4-nitro-phenyl)deschloroepibatidine (4-nitro-PFEB) analog exhibited the most pronounced antagonist activity among these analogs when tested electrophysiologically on α4β2 nAChRs. It inhibited ACh-induced currents in a concentrationdependent manner with an IC 50 of 0.1 µM and produced complete inhibition at ~1 µM concentration. 4-Nitro-PFEB at 0.1 µM concentration produced a four-fold rightward shift in the ACh concentration-response curve without altering maximum ACh-induced response. This inhibitory effect of 4-nitro-PFEB was voltage-and use-independent, and partially reversible at its 1 µM concentration. The rise and decay kinetics of ACh-induced currents was not altered in the presence of 4-nitro-PFEB. In contrast to α4β2 nAChRs, this compound did not affect α3β4 nAChR-mediated currents at ≤ 1µM (IC 50~6 3.9 µM). Overall, these functional data agree with previous binding and behavioral findings and suggest collectively that 4-nitro-PFEB is the most effective and selective antagonist of α4β2 versus α3β4 and α7 nAChRs among the tested analogs, acting on α4β2 nAChR through a competitive mechanism with a potency 17-fold higher than that of dihydro-β-erythroidine.
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To date nine α (α2-α9) and three β (β2-β4) subunits of neuronal nicotinic acetylcholine receptors (nAChRs) have been identified, cloned and functionally expressed. Biochemical, histological and physiological investigations indicate that the most abundant forms of nAChRs in the central nervous system are α4β2 and α7, while α3β4, though detected in some brain regions (habenulopeduncular system, cerebellum and locus ceruleus) predominates in the periphery (for review see (Smythies, 2005) ). The discovery that the α4β2 nAChR plays a crucial role in learning mechanism (Picciotto et al., 1995) , pain control (Marubio et al., 1999) and nicotine dependence (Lester et al., 2003; Picciotto et al., 1998) has stimulated efforts to develop potent neuronal nAChR subtype-selective compounds that readily penetrate the blood-brain barrier and exhibit reduced side effects. Synthetic analogs of a natural alkaloid epibatidine are of increasing interest because of its antinociceptive effects and high affinity to some nicotine receptor subtypes (α4β2>α3β2/4>α7) (Badio and Daly, 1994; Chavez-Noriega et al., 1997; Xiao and Kellar, 2004 ). The challenge is to design analogs that are devoid of epibatidine's toxicity and low nAChR subtype selectivity. Efforts to modify epibatidine's structure include changes in stereochemistry, replacement of the N-H with other groups, changes in the 2-chloropyridine ring, replacement of the 2-chloropyridine ring with bioisosteric rings, changes in the 7-azabicyclo[2.2.1]heptane ring system, and conformationally-constrained analogs (Carroll, 2004; Carroll et al., 2005; Huang et al., 2005; Wei et al., 2005) .
2-Fluoro-3-(substituted phenyl)deschloroepibatidine analogs ( Fig. 1) were obtained by replacement of the 2-chloro atom present in epibatidine by fluorine and addition of a 3-phenyl or a 3-or 4-substituted phenyl group to the pyridine ring bind. They bind with high affinity to α4β2
(the K i s varied from 9 to 87 pM) but not to α7 nAChRs . With the exception MOL (21782) 5 with potencies 2-4 times higher than that of mecamylamine, a nAChR subtype nonselective blocker (Papke et al., 2001) . In contrast to mecamylamine (Damaj et al., 1995) , they failed to block nicotine-induced hypothermia.
Currently available nAChR competitive antagonists are not sufficiently α4β2 subtype selective. Dihydro-β-erythroidine (DHβE) is an antagonist that inhibits human and rat α4β2-mediated responses with IC 50 s in the range of 0.1-1.9 µM (reviewed by Eaton et al., 2003) .
Comparative studies revealed that DHβE is 60-fold more potent in rat α4β2 than α3β4 nAChRs (Harvey and Luetje, 1996) , or in human α4β2 (Chavez-Noriega et al., 2000) than α3β4 (Stauderman et al., 1998) nAChRs. Further, DHβE appeared to possess 10-fold greater selectivity to human α4β4 than α4β2 nAChRs (Chavez-Noriega et al., 1997) . Structurally related to DHβE, erysodine has substantially greater affinity to α3β4 than to α4β2 nAChRs even though its greater affinity for α4β2 nAChRs than DHβE (Decker et al., 1995; Mansbach et al., 2000) .
Notably, both DHβE and erysodine exhibit low affinity to α7 nAChRs. Methyllycaconitine, which is another known competitive antagonist of α4β2 nAChRs, is 50-100 fold more selective for α7 than α4β2 nAChRs (Yum et al., 1996) and possesses significantly higher affinity for α6β2 than α4β2 nAChRs (Zoli et al., 2002) . The pyridinyl ether A-186253 is a recently reported compound with markedly higher binding affinity for α4β2 versus α3β4 and α7 nAChRs, but it appears to exhibit low functional selectivity and partial agonistic effect in both α4β2 and α3β4 nAChRs (Itier et al., 2004 ).
Here we report that 4-nitro-PFEB is a potent competitive antagonist of neuronal nAChRs that selectively inhibits α4β2-mediated currents with an IC 50 of 0.1 µM (17-fold more potent than DHβE). In α4β2 nAChRs, the inhibitory effect of 4-nitro-PFEB caused a shift of the ACh This article has not been copyedited and formatted. The final version may differ from this version. concentration-response curve typical for competitive antagonist, was both voltage-and useindependent, was not accompanied by alteration in the current kinetics, and was more pronounced after pre-exposure of the cell to the analog.
Materials and Methods
Cell transfection and culture. Stably transfected HEK 293 and SH-EP1 cells expressing rat α3β4 and human α4β2 neuronal nAChRs, respectively, were prepared as described previously (Zhang et al., 1999; Eaton et al., 2003) . Both cell lines were maintained at 37°C with 5% CO 2 in the incubator. Growth medium for HEK 293 cells was minimum essential medium supplemented with 10% fetal bovine serum, 100 U/ml penicillin, and 100 µg/ml streptomycin. Transfection was conducted by the calcium phosphate method. The stably transfected cell line was raised in selective growth medium containing 0.7 mg/ml of Geneticin (Invitrogen Corp, Carlsbad, CA).
Growth medium for SH-EP1 cells was Dulbecco's Modified Eagle's medium with high glucose supplemented with 10% heat inactivated horse serum, 5% fetal bovine serum, 100 U/ml penicillin, 100 µg/ml streptomycin, 8 mM L-glutamine, 1 mM sodium pyruvate, and 0.25 µg/ml amphotericin (all from Invitrogen Corp, Carlsbad, CA). Transfection was conducted by the electroporation method. This stably transfected cell line was raised in selective medium containing 0.5 mg/ml zeocin (Invitrogen) and 0.4 mg/ml hygromycin B (Roche Diagnostics Corp, Indianapolis, IN). RT-PCR analysis was used to confirm expression of nAChR subunit messages in the cells and immunoprecipitation-Western analyses using solubilized membrane samples from transfected cells clearly indicated that subunits were expressed as a protein and assembled together. Control experiments excluded possible activation of muscarinic ACh receptors by ACh application in both cell lines.
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7 Difference in species of the nAChRs used in this study (rat α3β4 and human α4β2) is due to current unavailability to us of these nAChR subtypes that would be functional and expressed in the cells at sufficiently high level. Rat and human nAChR subunits share 82-95 % sequence identity, and when are present in neuronal nAChR receptors of the same subunit composition provide them with numerous similarities in their properties (Albuquerque et al., 2000; Chavez-Noriega et al., 1997; Chavez-Noriega et al., 2000; Xiao and Kellar, 2004; Zhang et al., 1999) .
Whole-cell current recording. Functional expression of nAChRs was evaluated in the wholecell configuration of the patch-clamp technique using an Axopatch 200B amplifier (Molecular devices, Sunnyvale, CA). The patch electrodes, pulled from borosilicate glass capillaries (Sutter Instrument Company, Novato, CA), had a resistance of 2.5-3.5 MΩ when filled with internal solution containing 110 mM Tris phosphate dibasic, 28 mM Tris base, 11 mM EGTA, 2 mM MgCl 2 , 0.1 mM CaCl 2 and 4 mM Na-ATP (pH adjusted to 7.3 with Tris base) (Wu et al., 2004) .
In some cells ~85% of electrode resistance was compensated electronically, so that the effective series resistance in the whole-cell configuration was accepted when less than 20 MΩ. Stably transfected HEK and SH-EP1 cells were studied for 2 to 3 days after plating the cells on the 15-mm round plastic cover slips (Thermanox, Nalge Nunc, Napierville, IL). Generation of voltageclamp protocols and acquisition of the data were carried out using pCLAMP 9.0 software (Molecular Devices). Sampling frequency was 5 kHz and current signals were filtered at 5 or 10 kHz before digitization and storage. All experiments were performed at room temperature (22- Olympus Corporation, Tokyo, Japan) and were bathed in a solution containing 140 mM NaCl, 3 mM KCl, 2 mM MgCl 2 , 25 mM D-glucose, 10 mM HEPES and 2 mM CaCl 2 (pH adjusted to 7.4 with Tris base). The experimental chamber was constantly perfused with control bathing solution (1-2 ml/min). The amplitude and time course of currents mediated by neuronal nAChRs is highly dependent on the speed of drug application. The high speed solution exchange system, HSSE-2 (ALA Scientific Instruments, Westbury, NY), is able to switch rapidly between control and four test solutions delivered through two output tubes which face each other at 90° in the same plane.
Under optimal conditions, the delay in switching between solutions is ~10 ms. Data presented herein were obtained through subtraction from the leak current. eliciting a half maximum response and nH is a Hill coefficient. A similar approach was used to evaluate agonist effect of 4-nitro-PFEB in α3β4 nAChRs.
Results are presented as the mean ± S.E.M for the number of cells (n) or as averaged means. Where appropriate Student's t-test for paired data was used, and values of P ≤ 0.05 were regarded as significant.
Drugs. ACh chloride, DHβE and salts were purchased from Sigma Aldrich (Atlanta, GA). Six different 2-fluoro-3-(substituted phenyl)deschloroepibaitidine analogs ( Fig. 1 ) were synthesized as previously reported .
Results
ACh-induced whole-cell currents were elicited by pulse application (200 ms) of ACh on SH-EP1 or HEK 293 cells stably expressing human α4β2 or rat α3β4 nAChRs, respectively. In agreement with previous studies (Wu et al., 2004; Zhang et al., 1999) , our control experiments indicated that the α4β2 nAChRs (EC 50~2 3 µM) were more sensitive to ACh than α3β4
Inhibitory potency of the analogs on α4β2 and α3β4 nAChRs. Based on the previously reported potent antagonist activity of 2-fluoro-3-(substituted phenyl)deschloroepibatidine analogs examined in nicotine-induced analgesia tests and evidence that the antinociceptive effect of nicotine occur via activation of neuronal nAChRs (Bitner et al., 2000; Marubio et al., 1999) , the potency of the 2-fluoro-3-(substituted phenyl)deschloroepibatidine analogs in inhibiting the neuronal nAChR activity if these two nAChR subtypes was determined. The cell under recording was exposed to an EC 50 concentration of ACh and 30 s later to ACh at the same concentration in the presence of various This article has not been copyedited and formatted. The final version may differ from this version. concentrations of the analog. When the inhibitory effect of the analog was reversible, two more concentrations were tested on the same cell. Except for the 3-fluoro-PFEB, the peak amplitude of ACh-induced currents was decreased by epibatidine analogs more effectively in α4β2 than in α3β4 nAChRs. Different potencies of the analogs for each receptor subtype are presented in Fig. 2A-B. The IC 50 s and their ratios for α4β2 and α3β4 nAChRs, and Hill coefficients for the analogs are summarized in Table 1 . Comparison of IC 50 s for six 2-fluoro-3-(substituted phenyl)deschloroepibatidine analogs in the two nAChRs subtypes revealed that 4-nitro-PFEB induced half-maximum inhibition of α4β2 nAChR currents at lower concentration (0.1 µM) than the other five analogs ( Fig. 2A) . In contrast, in α3β4 nAChRs the 4-nitro-PFEB was less potent as an antagonist than the other analogs with a maximal inhibitory effect of 82 ± 1.9 % and an IC 50 value of 63.9 µM (Fig.2B) . Thus, 4-nitro-PFEB analog was 639-fold more effective as antagonist in α4β2 than α3β4 nAChRs. conditions. The IC 50 for DHβE in human α4β2 nAChRs was determined as ~1.7 µM ( Fig. 2A) , being 13-fold lower than that for rat α3β4 nAChRs (~22 µM) (Fig. 2B ). Less than 50%
inhibition occurred in the presence of 1 µM of DHβE (Fig. 2E) , and an increase of the DHβE This article has not been copyedited and formatted. The final version may differ from this version.
concentration up to 10 µM suppressed the current by 80% ( Fig. 2A) . In contrast to α4β2, AChinduced current mediated by α3β4 receptors was not affected in the presence of 1 µM 4-nitro-PFEB ( Fig. 2F ) and was inhibited only by 22 ± 8% at its 10 µM concentration (Fig. 2B) .
Control experiments were performed to test the 2-fluoro-3-(substituted phenyl)deschloroepibatidine analogs for possible agonist activity, when the cells were examined first for the presence of nAChR functional expression, followed by the application of each analog depicted in Figure 1 . No substantial current activation was elicited at either 1 or 10 µM concentrations of the analogs at α4β2 nAChRs. The agonist effect of 4-nitro-PFEB, the most potent α4β2 antagonist, is shown in a representative cell in Figure 3A . In α3β4 nAChRs, the analogs applied alone at a 10 µM concentration induced some current activation, when expressed as a percent of the current induced by 100 µM ACh, averaged (n=4-5 cells) 4.6, 1.3, 4.8, 1.8, 31.8 and 6.0% for 3-fluoro-, 4-fluoro-, 3-chloro-, 4-chloro-, 4-nitro-and 3-nitro-PFEBs, respectively. At 1 µM 4-nitro-PFEB induced ≤10% of the half-maximum ACh-induced wholecell response in α3β4 nAChRs. Detailed examination of the effect of the 4-nitro-PFEB by itself on α3β4 nAChRs revealed that the compound behaved as a weak partial agonist with an intrinsic activity of 23.7 ± 1.8 %, when normalized to that produced by the full agonist ACh at 1 mM concentration, and EC 50 value of ~3.7 µM (Fig. 3B) . It is important to note that at concentrations ≤1 µM the agonist effect of 4-nitro-PFEB on α3β4 nAChRs was negligible.
Mechanism of action of the 4-nitro-PFEB as an α4β2 nAChR. 4-Nitro-PFEB was selected for studies to probe the mechanism of inhibition of the α4β2 nAChR mediated currents.
The ACh concentration-response relationship in the absence of the analog yielded an EC 50 of ~23 µM for ACh (Fig. 4) . In the presence of the 0.1 µM 4-nitro-PFEB, the ACh concentrationThis article has not been copyedited and formatted. The final version may differ from this version. Effect of the 4-nitro-PFEB on the kinetics of ACh-induced currents in α4β2
nAChRs. The effect of the analog at its IC 50 concentration on the rise and decay phase of the currents was studied at holding potential of -80 mV. The currents recorded in the presence of the analog were normalized in their peak amplitude to the corresponding control current (Fig. 5) . normalizing all the responses in the presence of 4-nitro-PFEB relative to the peak amplitude of the control ACh-induced currents at the same holding potential (Fig. 6C, left panel) . The ratio of the peak amplitude evoked by ACh in the presence of the analog to the amplitude of the current evoked by ACh alone did not change significantly at the holding potentials from -100 mV to -20 mV (Fig. 6C , right panel, n = 4). Thus, the reduction by the analog of the peak ACh-induced currents in α4β2 nAChRs was voltage-independent.
This article has not been copyedited and formatted. The final version may differ from this version. 
Discussion
Our results demonstrate that 2-fluoro-3-(4-nitro-phenyl)deschloroepibatidine acts as a potent competitive antagonist at α4β2 nAChRs which give rise to the majority of nicotinic responses in the central nervous system. Based on the IC 50 values obtained in this study, the 4-nitro-PFEB appeared to be 17-fold more potent in inhibiting α4β2 nAChR mediated currents than DHβE, which is currently known as one of the most potent competitive antagonists of α4β2 nAChRs, and 639-fold more potent in inhibiting α4β2 than α3β4 nAChRs.
Higher potency of 4-nitro-PFEB than of the other 2-fluoro-3-(substituted phenyl)deschloroepibatidine analogs in inhibiting ACh-induced currents in α4β2 nAChRs is consistent with its higher affinity in binding assays (K i~9 pM) and more pronounced antagonist effect of nicotine-induced analgesia (AD 50~0 .12 mg/kg) . This analgesia, as measured in the hot-plate test, occurs at the supraspinal level and has been shown to be mediated by α4β2 nAChRs (Marubio et al., 1999) . On the other hand, the 3-fluoro-PFEB, that produced only 20% inhibition of ACh-induced currents at 10 µM concentration, exhibited little analgesia in the hot-plate test (20% at 1 mg/kg) and bound with lower affinity than the other five analogs to nAChR receptors in the rat brain (K i~8 7 pM) mg/kg), receptor affinity and functional data for 3-nitro-PFEB.
The inhibitory potency of 4-nitro-PFEB was compared under similar experimental conditions to that of another routinely used competitive antagonist of the α4β2 nAChRs, DHβE, that has a K i~1 4.3 nM for nicotinic receptors in the rat brain (Damaj et al., 1995) . DHβE's AD 50
for blocking nicotine antinociception in the tail-flick test was 0.45 mg/kg (Damaj et al., 1995) compared to the AD 50 of 0.003 mg/kg for 4-nitro-PFEB. The IC 50 s for these two competitive antagonists obtained under similar experimental conditions indicated that 4-nitro-PFEB was 17-fold more potent than DHβE in inhibition of α4β2 nAChR activity. Indeed, 1 µM concentration of 4-nitro-PFEB was much more effective in inhibiting ACh-induced current in α4β2 nAChRs than a similar concentration of DHβE. It was necessary to increase the DHβE concentration to 10 µM in order to achieve a similar inhibition as induced by 1 µM 4-nitro-PFEB. The IC 50 for DHβE determined in our study using whole-cell recordings from SH-EP1 cells stably expressing human α4β2 nAChRs (1.7 µM) corresponds well to values reported for human α4β2 nAChRs using 86 Rb + efflux in a different expression systems, such as SH-EP1 cells (1.5 µM) (Eaton et al., 2003) or HEK 293 cells (1.9 µM) (Gopalakrishnan et al., 1996) . This IC 50 value is 13-fold lower than the IC 50 for DHβE for rat α3β4 nAChRs expressed in HEK 293 cells (22 µM) which is very similar to that (23 µM) for rat α3β4 nAChRs expressed in Xenopus oocytes (Harvey and Luetje, 1996) . Similarly to partial recovery after the methyllycaconitine effect in hippocampal nicotinic receptors (Alkondon et al., 1992) , the 4-nitro-PFEB (1 µM) inhibition of α4β2 nAChRs was reversible only in part after a 4 min wash out, whereas after 10 µM DHβE inhibition the This article has not been copyedited and formatted. The final version may differ from this version. receptors for ACh was not affected by 4-nitro-PFEB, and the inhibitory effect of the analog on current amplitude was more pronounced after pre-exposure of the cell, suggesting that the analog may also act on α4β2 nAChR channels that are not opened. Further, the reduction of the peak amplitude of ACh-induced currents in the presence of 4-nitro-PFEB was voltage-independent, suggesting that the analog does not interact with sites located inside the ion channel pore. The fact that the reduction of the ACh-induced current amplitude was not accompanied by an alteration of the rise time was probably rather due to the limitations in the speed of the application system, while the absence of the effect on the decay kinetics of the currents suggests that 4-nitro-PFEB does not affect desensitization of the receptor. Collectively, our findings support the notion that 4-nitro-PFEB is a competitive antagonist of α4β2 nAChRs. It is important to mention that it lacked significant agonistic activity at α4β2 nAChRs.
4-Nitro-PFEB also exhibits neuronal nAChR selectivity. 4-Nitro-PFEB bound with high affinity to α4β2 but not to α7 neuronal nAChRs in the rat brain . In contrast to its ability to inhibit α4β2 nAChRs, a much higher concentration was required to inhibit AChinduced currents in α3β4 nAChRs, only 60% inhibition was achieved at a 100 µM concentration.
Though 4-nitro-PFEB exhibited weak partial agonist activity in α3β4 nAChRs, it is important to stress that at 1 µM concentration, at which 4-nitro-PFEB induced almost complete inhibition of This article has not been copyedited and formatted. The final version may differ from this version. α4β2 nAChR activity, it did not inhibit markedly ACh-induced currents in α3β4 nAChRs nor evoke substantial activation of α3β4 nAChRs.
Considering the current lack of α4β2 nAChR subtype selective competitive antagonists and the heterogeneity of nAChR subtypes in a single neuron (e.g. Azam et al., 2002) , the novel compound, 2-fluoro-3-(4-nitro-phenyl)deschloroepibatidine, may serve as a pharmacological tool for specific isolation of responses mediated by native neuronal nAChRs containing the α4β2 subunit combination (Dani et al., 2004) . Because of high binding affinity of 4-nitro-PFEB to α4β2 nAChRs , this compound may serve as a guide for the development of additional α4β2 subtype selective probes.
A subtype-specific neuronal nAChR antagonist has properties suggesting that it can be utilized as a therapeutical agent. α4β2 nAChRs are expressed in a high density in the ventral tegmental area, substantia nigra and nucleus accumbens, which are thought to play a central role in the reinforcing effect of nicotine (Wooltorton et al., 2003) . α4β2 nAChRs are localized on pre-or postsynaptic sites, and presynaptically modulate dopamine release (Zhou et al., 2001 ).
Nicotine-induced upregulation of α4β2 AChRs (Vallejo et al., 2005; Picciotto et al., 1995) on presynaptic dopamine-releasing terminals probably leads to enhanced presynaptic depolarization and an increased release of dopamine. In support of this premise, self-administration of nicotine is reduced in β2 subunit knockout mice (Picciotto et al., 1998) . Another supportive finding is that the antidepressant bupropion, that affects neuronal nAChRs and dopamine/norepinephrine transporters is used clinically for smoking cessation (Ross and Williams, 2005; Slemmer et al., 2000) . In contrast to bupropion-induced inhibition of neuronal nAChRs, which is not subtype selective (α3β4>α4β2) (Alkondon and Albuquerque, 2005) , 4-nitro-PFEB, is a potent competitive selective antagonist of α4β2 versus α7 and α3β4 nAChRs. Therefore, this
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